E-viri
Recenzirano
Odprti dostop
-
Toffalori, Cristina; Zito, Laura; Gambacorta, Valentina; Riba, Michela; Oliveira, Giacomo; Bucci, Gabriele; Barcella, Matteo; Spinelli, Orietta; Greco, Raffaella; Crucitti, Lara; Cieri, Nicoletta; Noviello, Maddalena; Manfredi, Francesco; Montaldo, Elisa; Ostuni, Renato; Naldini, Matteo M; Gentner, Bernhard; Waterhouse, Miguel; Zeiser, Robert; Finke, Jurgen; Hanoun, Maher; Beelen, Dietrich W; Gojo, Ivana; Luznik, Leo; Onozawa, Masahiro; Teshima, Takanori; Devillier, Raynier; Blaise, Didier; Halkes, Constantijn J M; Griffioen, Marieke; Carrabba, Matteo G; Bernardi, Massimo; Peccatori, Jacopo; Barlassina, Cristina; Stupka, Elia; Lazarevic, Dejan; Tonon, Giovanni; Rambaldi, Alessandro; Cittaro, Davide; Bonini, Chiara; Fleischhauer, Katharina; Ciceri, Fabio; Vago, Luca
Nature medicine, 04/2019, Letnik: 25, Številka: 4Journal Article
Transplantation of hematopoietic cells from a healthy individual (allogeneic hematopoietic cell transplantation (allo-HCT)) demonstrates that adoptive immunotherapy can cure blood cancers: still, post-transplantation relapses remain frequent. To explain their drivers, we analyzed the genomic and gene expression profiles of acute myeloid leukemia (AML) blasts purified from patients at serial time-points during their disease history. We identified a transcriptional signature specific for post-transplantation relapses and highly enriched in immune-related processes, including T cell costimulation and antigen presentation. In two independent patient cohorts we confirmed the deregulation of multiple costimulatory ligands on AML blasts at post-transplantation relapse (PD-L1, B7-H3, CD80, PVRL2), mirrored by concomitant changes in circulating donor T cells. Likewise, we documented the frequent loss of surface expression of HLA-DR, -DQ and -DP on leukemia cells, due to downregulation of the HLA class II regulator CIITA. We show that loss of HLA class II expression and upregulation of inhibitory checkpoint molecules represent alternative modalities to abolish AML recognition from donor-derived T cells, and can be counteracted by interferon-γ or checkpoint blockade, respectively. Our results demonstrate that the deregulation of pathways involved in T cell-mediated allorecognition is a distinctive feature and driver of AML relapses after allo-HCT, which can be rapidly translated into personalized therapies.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.